These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10935701)

  • 21. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations.
    Cinti P; Pretagostini R; Arpino A; Tamburro ML; Mengasini S; Lattanzi R; De Simone P; Berloco P; Molajoni ER
    Transplantation; 2005 May; 79(9):1154-6. PubMed ID: 15880060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
    Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of donor antigen-specific hyporeactivity with allogeneic microchimerism in kidney and lung recipients.
    Reinsmoen NL; McSherry C; Chavers B; Hertz MI; Matas AJ
    Pediatr Nephrol; 1995; 9 Suppl():S35-9. PubMed ID: 7492484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A clinically feasible approach to induce delayed tolerance in recipients of prior kidney or vascularized composite allotransplants.
    Chen B; Xu H; Corbin DR; Ildstad ST
    Transplantation; 2012 Oct; 94(7):671-8. PubMed ID: 22948444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients.
    Crop MJ; Baan CC; Korevaar SS; Ijzermans JN; Alwayn IP; Weimar W; Hoogduijn MJ
    Transplantation; 2009 Mar; 87(6):896-906. PubMed ID: 19300194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of post-transplant immune status in recipients of liver/bone marrow allografts.
    Chatzipetrou MA; Mathew JM; Kenyon NS; Esquenazi V; Miller J; Ricordi C; Tzakis AG
    Hum Immunol; 1999 Dec; 60(12):1281-8. PubMed ID: 10626743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulated donor-specific T-cell reactivity during successful tapering of immunosuppression after kidney transplantation.
    van Besouw NM; van der Mast BJ; de Kuiper P; Smak regoor PJ; Vaessen LM; Ijzermans JN; van Gelder T; Weimar W
    Clin Exp Immunol; 2002 May; 128(2):388-93. PubMed ID: 11985532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor-specific hypo-responsiveness occurs in simultaneous liver-kidney transplant recipients after the first year.
    Taner T; Gustafson MP; Hansen MJ; Park WD; Bornschlegl S; Dietz AB; Stegall MD
    Kidney Int; 2018 Jun; 93(6):1465-1474. PubMed ID: 29656904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation.
    Gloor JM; DeGoey S; Ploeger N; Gebel H; Bray R; Moore SB; Dean PG; Stegall MD
    Transplantation; 2004 Jul; 78(2):221-7. PubMed ID: 15280682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stable T-cell reactivity after successful tapering of azathioprine in HLA-identical living-related kidney transplant recipients despite minor histocompatibility antigen mismatches.
    Gerrits JH; van de Wetering J; Postma S; Drabbels JJ; Vaessen LM; IJzermans JN; Rischen J; Claas FH; Weimar W; van Besouw NM
    Nephrol Dial Transplant; 2007 Feb; 22(2):353-61. PubMed ID: 17124279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Living-Donor Kidney Transplant With Preformed Donor-Specific Antibodies.
    Itabashi Y; Aikawa A; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Arai T; Kawamura T; Hamasaki Y; Sakai K; Shishido S
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):43-49. PubMed ID: 30777522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of in vitro donor-specific hyporesponsiveness in renal allograft recipients as demonstrated by the MLR.
    Ghobrial II; Morris AG; Booth LJ
    Transpl Int; 1994; 7(6):420-7. PubMed ID: 7865106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4+CD25bright+ regulatory T cells can mediate donor nonreactivity in long-term immunosuppressed kidney allograft patients.
    Velthuis JH; Mol WM; Weimar W; Baan CC
    Am J Transplant; 2006 Dec; 6(12):2955-64. PubMed ID: 17294523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune status of recipients following bone marrow-augmented solid organ transplantation.
    Zeevi A; Pavlick M; Lombardozzi S; Banas R; Pappo O; Rao AS; Fontes P; Demetris J; Shapiro R; Dodson F
    Transplantation; 1995 Feb; 59(4):616-20. PubMed ID: 7878767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multiplex bead array analysis to monitor donor-specific cytokine responses after withdrawal of immunosuppression in HLA-identical living related kidney transplant patients.
    Gerrits JH; van de Wetering J; van Beelen E; Claas FH; Weimar W; van Besouw NM
    Transplant Proc; 2009 Jun; 41(5):1577-82. PubMed ID: 19545683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
    Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
    Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peri-operative immunoadsorption in sensitized renal transplant recipients.
    Haas M; Böhmig GA; Leko-Mohr Z; Exner M; Regele H; Derfler K; Hörl WH; Druml W
    Nephrol Dial Transplant; 2002 Aug; 17(8):1503-8. PubMed ID: 12147802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
    Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
    Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients.
    Ciancio G; Burke GW; Garcia-Morales R; Suzart K; Rosen A; Ricordi C; Kenyon NS; Mathew JM; Tzakis AG; Esquenazi V; Miller J
    Transplantation; 2002 Aug; 74(4):488-96. PubMed ID: 12352907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
    J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.